论文部分内容阅读
目的 了解重组人生长激素 (rhGH)对扩张性心肌病 (DCM )和缺血性心肌病 (ICM )患者心功能的影响和安全性。方法 30例缺血性心肌病和扩张性心肌病所致慢性心力衰竭患者 (ICM :治疗组 1 1例 ,对照组 1 1例 ;DCM :治疗组 4例 ,对照组 4例 ) ,两组患者均行常规抗心力衰竭治疗 ,同时治疗组隔日腹部皮下注射rhGH 4U ,共 1个月。治疗前后分别进行心脏彩色超声、血流动力学及血清胰岛素生长因子 (IGF) Ⅰ、血浆血管紧张素(Ang) Ⅱ的测定。结果 治疗组的左室收缩功能较对照组明显改善 (P <0 0 5) ,舒张功能两组之间差异无显著性 ;血清IGF Ⅰ治疗组较对照组明显升高 ;血浆Ang Ⅱ治疗组较对照组降低明显 ,但治疗后两组比较差异无显著性 (P>0 0 5)。结论 ①rhGH可明显改善ICM和DCM患者的左室收缩功能。②rhGH治疗过程是安全的
Objective To investigate the effect and safety of recombinant human growth hormone (rhGH) on cardiac function in patients with dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM). Methods Thirty patients with ischemic cardiomyopathy and dilated cardiomyopathy who had chronic heart failure (ICM: 11 in the treatment group, 11 in the control group, 4 in the DCM group and 4 in the control group) All patients were treated with conventional anti-heart failure, while rhGH 4U was injected subcutaneously in the treatment group every other day for 1 month. Color echocardiography, hemodynamics, serum insulin growth factor (IGF) Ⅰ and plasma angiotensin Ⅱ were measured before and after treatment. Results Compared with the control group, the left ventricular systolic function in the treatment group was significantly improved (P <0 05), while the diastolic function was not significantly different between the two groups. Serum IGF Ⅰ treatment group was significantly higher than the control group; plasma Ang Ⅱ treatment group The control group decreased significantly, but after treatment there was no significant difference between the two groups (P> 0.05). Conclusion ① rhGH can significantly improve left ventricular systolic function in patients with ICM and DCM. ② rhGH treatment is safe